Oral DTPA for radionuclide chelation

Details Oral DTPA for radionuclide chelation Oral DTPA for radionuclide chelation

2011-03-29

2011-03-29

Hartley, Michael G (Department: 1618)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

C424S001650

Reexamination Certificate

active

07914767

ABSTRACT:
A composition for oral radionuclide chelation therapy comprises a DTPA chelate selected from Zn-DTPA and Ca-DTPA and a permeation enhancer that preferentially increases jejunal uptake of the DTPA chelate. The composition has a DTPA chelate bioavailability of at least 10% of the chelate when orally administered to a mammal.

REFERENCES:
patent: 5730968 (1998-03-01), Butterfield et al.
patent: 6017522 (2000-01-01), Butterfield
patent: 2004/0191169 (2004-09-01), Scheinberg et al.
patent: 2008/0029625 (2008-02-01), Talton
Yüksel et al. (Eur. J. Pharm. Biopharm. 2003, 56, 453-459).
{hacek over (S)}imonović et al. (J. Appl. Toxicol. 1986, 6, 109-111).
Conrad et al. (J. Cell Biol. 1986, 103, 439-450).
Strickley (Pharm. Res. 2004, 21, 201-230).
Schulze et al. (Int. J. Pharm. 2005, 300, 67-75).
Duffield J R et al: “Computer simulation of metal ion equilibria in biofluids. IV. plutonium speciation in human blood plasma and chelation therapy using polyaminopolycarboxylic acids” Journal of Inorganic Biochemistry, Elsevier Inc, US, vol. 20, No. 3, Mar. 1, 1984, pp. 199-214.
Phan et al: “Pharmacokinetics of DTPA entrapped in conventional and longcirculating liposomes of different size for plutonium decorporation” Journal of Controlled Release, Elsevier, Amsterdam, NL, vol. 110, No. 1, Dec. 10, 2005, pp. 177-188.
Kaminski M 0 et al: “Detoxification of blood using injectable magnetic nanospheres: A conceptual technology description” Journal of Magnetism and Magnetic Materials, Elsevier Science Publishers, Amsterdam, NL, vol. 293, No. 1, May 1, 2005, pp. 398-403.
Blank M L et al: “Liposomal preparations of calcium- or zinc-DTPA have a high efficacy for removing colloidal ytterbium-169 from rat tissues” Toxicology, Limerick, IR, vol. 30, No. 4, Apr. 16, 1984, pp. 275-281.
Aungst B J: “Intestinal Permeation Enhancers” Journal of Pharmaceutical Sciences, American Pharmaceutical Association, Washington, US, vol. 89, No. 4, Apr. 1, 2000, pp. 429-442.
Bulman R A et al: “Investigations Into Techniques for Removing Intra Cellular Plutonium 2. Complexing Agents Bound to Macro Molecules” Health Physics, Lippincott, Williams & Wilkins, Hagerston, MD, USA, vol. 40, No. 2, Jan. 1, 1981, pp. 228-231.
Kargacin B. et al.: ‘Reduction of strontium-85 cesium-137 iodine-131 andcerium-141 retention in rats by simultaneous oral administration of calcium alginate, ferrihexaxyanoferrate(II). KI, ZN-DTPA’ Health Physics vol. 49, No. 5, 1985, pp. 859-864 (abstract).
Kostial K. et al.: ‘Oral zinc-OTPA treatment reduces cadmium absorption and retention in rats’ Toxicology Letters vol. 39, No. 1, 1987, pp. 71-76.
Extended European search report for 07808982.8, corresponding to US 11705938, Mar. 16, 2010.
Aschar-Sobbi et al. “High Sensitivity, Quantitative Measurements of Polyphosphate Using a New DAPI-Based Approach” J Fluorese (2008) 18:859-866.

Affiliated with

Also associated with

Rating

Oral DTPA for radionuclide chelation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oral DTPA for radionuclide chelation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral DTPA for radionuclide chelation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2732084